According to a market report by Lucintel, the future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3 billion by 2030 from $1 billion in 2024 at a CAGR of 18.7% from 2024 to 2030. The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.
A more
than 150-page report to understand trends, opportunity and forecast in global viral
vector manufacturing market to 2030 by type (adenovirus, retrovirus,
adeno-associated virus, lentivirus, plasmid DNA, and others), workflow
(upstream manufacturing and downstream manufacturing), application (cell &
gene therapy, vaccinology, and research & other applications), end use
(pharmaceutical & biopharmaceutical, research institutes, and others), and
region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecasts that cell and gene therapy is expected to witness the highest growth
over the forecast period due to the growing demand for cell and gene therapies
for the treatment of a wide range of diseases, including cancer, rare diseases,
and genetic disorders.
Within
this market, pharmaceutical and biopharmaceutical will remain the largest
segment because these pharmaceutical and biopharmaceutical companies are developing
and commercializing viral vector-based therapies for a wide range of diseases,
including cancer, rare diseases, and infectious diseases.
Download
sample by clicking on viral
vector manufacturing market.
North
America is expected to witness the highest growth over the forecast period due
to increasing demand for viral vector-based therapies from the pharmaceutical
and biotechnology industries in the region.
Merck,
Lonza, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Cobra
Biologics, Catalent, Wuxi Biologics, Takara Bio, Waisman Biomanufacturing,
Genezen Laboratories are the major suppliers in the viral vector manufacturing market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Diesel Electric Submarine Market
No comments:
Post a Comment